Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 28Carcinoma, Hepatocellular 25Colorectal Neoplasms 23Carcinoma, Non-Small-Cell Lung 13Melanoma 12Stomach Neoplasms 10Colonic Neoplasms 10Liver Neoplasms 9Neoplasm Metastasis 8Squamous Cell Carcinoma of Head and Neck 7Carcinoma, Transitional Cell 7Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Ovarian Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Prostatic Neoplasms 5Lung Neoplasms 5Gastrointestinal Stromal Tumors 5Esophageal Neoplasms 5Carcinoma 5Urinary Bladder Neoplasms 4Turcot syndrome 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Sarcoma 4Mesothelioma 4Endometrial Neoplasms 4Cholangiocarcinoma 4Carcinoma, Merkel Cell 4

Interventions

lutetium Lu 177 dotatate 8lanreotide 4copper dotatate CU-64 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4pasireotide 3Magnetic Resonance Spectroscopy 3Lutetium-177 3Lutetium 3gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2Irinotecan 2Ga(III)-DOTATOC 2Everolimus 2Etoposide 2Carboplatin 2zimberelimab 1regorafenib 1pembrolizumab 1irinotecan sucrosofate 1folfirinox 1famitinib 1cabozantinib 1arginyllysine 1abemaciclib 1X-Rays 1Sunitinib 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × Ipilimumab × Gastrointestinal × Clear all
NCT05262556 2025-08-07

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Case Comprehensive Cancer Center

Phase 1 Active not recruiting
15 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡